This is an investigational study. Both WBRT and SRS radiation are FDA approved for local control of metastatic and primary tumors. Nivolumab is FDA approved and commercially available for the treatment of melanoma and NSCLC. Ipilimumab is FDA approved and commercially available for the treatment of melanoma. It is considered investigational to use radiation therapy, nivolumab, and ipilimumab to treat NSCLC. The study doctor can explain how the study drugs are designed to work.